A new paediatric formulation of the HIV medicine Triumeq (abacavir, dolutegravir and lamivudine) has been approved by the US Food and Drug Administration, extending the treatment to children who otherwise would go unprotected. An estimated 1.7 million children globally were living with HIV in 2020 with most deaths from the disease occurring during the first five years of life, according to the Joint United Nations Programme on HIV/AIDS.
